1
|
Jennings MC, Sauer M, Manchester C, Soeters HM, Shimp L, Hyde TB, Parashar U, Burgess C, Castro B, Hossein I, Othepa M, Payne DC, Tate JE, Walldorf J, Privor-Dumm L, Richart V, Santosham M. Supporting evidence-based rotavirus vaccine introduction decision-making and implementation: Lessons from 8 Gavi-eligible countries. Vaccine 2024; 42:8-16. [PMID: 38042696 PMCID: PMC10733863 DOI: 10.1016/j.vaccine.2023.11.035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 11/05/2023] [Accepted: 11/17/2023] [Indexed: 12/04/2023]
Abstract
Despite the 2009 World Health Organization recommendation that all countries introduce rotavirus vaccines (RVV) into their national immunization programs, just 81 countries had introduced RVV by the end of 2015, leaving millions of children at risk for rotavirus morbidity and mortality. In response, the Rotavirus Accelerated Vaccine Introduction Network (RAVIN) was established in 2016 to provide support to eight Gavi-eligible countries that had yet to make an RVV introduction decision and/or had requested technical assistance with RVV preparations: Afghanistan, Bangladesh, Benin, Cambodia, Democratic Republic of Congo, Lao People's Democratic Republic, Myanmar, and Nepal. During 2016-2020, RAVIN worked with country governments and partners to support evidence-based immunization decision-making, RVV introduction preparation and implementation, and multilateral coordination. By the September 2020 program close-out, five of the eight RAVIN focus countries successfully introduced RVV into their routine childhood immunization programs. We report on the RAVIN approach, describe how the project responded collectively to an evolving RVV product landscape, synthesize common characteristics of the RAVIN country experiences, highlight key lessons learned, and outline the unfinished agenda to inform future new vaccine introduction efforts by countries and global partners.
Collapse
Affiliation(s)
- Mary Carol Jennings
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
| | - Molly Sauer
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA.
| | | | - Heidi M Soeters
- U.S. Centers for Disease Control and Prevention, Atlanta, USA
| | - Lora Shimp
- JSI Research and Training Institute, Arlington, USA
| | - Terri B Hyde
- U.S. Centers for Disease Control and Prevention, Atlanta, USA
| | - Umesh Parashar
- U.S. Centers for Disease Control and Prevention, Atlanta, USA
| | | | - Brian Castro
- JSI Research and Training Institute, Arlington, USA
| | | | | | - Daniel C Payne
- U.S. Centers for Disease Control and Prevention, Atlanta, USA
| | | | - Jenny Walldorf
- U.S. Centers for Disease Control and Prevention, Atlanta, USA
| | - Lois Privor-Dumm
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
| | | | - Mathuram Santosham
- Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA; International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
| |
Collapse
|